C. Cirrincione - Concepedia

Author

C. Cirrincione

Memorial Sloan Kettering Cancer Center

Also Known As

C Cirrincione, C. Cirrincione, C.T. Cirrincione, CT Cirrincione

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center University of North Carolina at Chapel Hill University of Vermont Duke Medical Center Duke University

About

C. Cirrincione is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.4K
2	Health Sciences	5	5	510
3	Orthopaedics	2	2	321
4	General Surgery	1	1	52
5	Neurology	1	1	178

C. Cirrincione

Publications

Citations

H-Index

Page 1

	Year	Citations
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. C. Focan, S. M. Steinberg, M Blichert-Toft, PubMed	1998	2.2K
Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Bosl Gj, Geller Nl, C. Cirrincione, PubMed Surgical OncologyCancer ManagementPrognosisCancer RegistrationTesticular Tumours	1983	289
Primary CNS lymphoma Lisa M. DeAngelis, J Yahalom, M.‐H. Heinemann, Neurology	1990	270
Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Raphael S. Werner, Beryl McCormick, Jeanne A. Petrek, Radiology ObesityBreast OncologyPersistent AeMedicineCancer Management	1991	269
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. Mark G. Kris, Richard J. Gralla, Leslie B. Tyson, Journal of Clinical Oncology Drug SafetyTherapeutic Drug MonitoringOncologyClinical TherapeuticMedicine	1989	240
Single brain metastases: surgery plus radiation or radiationalone Roy A. Patchell, C. Cirrincione, H Thaler, Neurology Neuro-oncologySurgical OncologyRadiation TherapyBrain MetastasesMedicine	1986	178
CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC Andrew D. Seidman, Donald A. Berry, C. Cirrincione, Journal of Clinical Oncology Breast OncologyCancer ManagementPathologyPharmacotherapyW P	2004	133
Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance) W. M. Sikov, DA Berry, CM Perou, Cancer Research Breast OncologyCancer EpidemiologyOverall SurvivalPcr RateMedicine	2016	86
Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Mack Roach, C. Cirrincione, Daniel R. Budman, PubMed	1997	70
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. Mary J. Laughlin, Dean McGaughey, James Crews, Journal of Clinical Oncology	1998	64

Page 1